Search Results - "Baldelli, A.M."

P211 Phase 2 neoadjuvant trial: myocet (M), cyclophosphamide (C) +/− trastuzumab (T) and paclitaxel (P) +/− T by Pistilli, B, Benedetti, G, Rossi, D, Baldelli, A.M, Magalotti, C, Casadei, V, Foghini, L, Staffolani, M, Fiorentini, G, Latini, L

Get full text

Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD) by Cascinu, S., Graziano, F., Ferraù, F., Catalano, V., Massacesi, C., Santini, D., Silva, R. R., Barni, S., Zaniboni, A., Battelli, N., Siena, S., Giordani, P., Mari, D., Baldelli, A. M., Antognoli, S., Maisano, R., Priolo, D., Pessi, M. A., Tonini, G., Rota, S., Labianca, R.

“…Background To evaluate the safety and efficacy of the novel raltitrexed/oxaliplatin combination (TOMOX) as first-line chemotherapy for patients with advanced…”
Get full text

Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer by Catalano, V., Loupakis, F., Graziano, F., Bisonni, R., Torresi, U., Vincenzi, B., Mari, D., Giordani, P., Alessandroni, P., Salvatore, L., Fornaro, L., Santini, D., Baldelli, A.M., Rossi, D., Giustini, L., Silva, R.R., Falcone, A., D'Emidio, S., Rocchi, M., Luzi Fedeli, S.

“…Previous studies investigating the prognostic role of mucinous histology of colorectal cancer produced conflicting results. This retrospective analysis was…”
Get full text

A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer by Graziano, F., Catalano, V., Baldelli, A. M., Giordani, P., Testa, E., Lai, V., Catalano, G., Battelli, N., Cascinu, S.

“…Background: Docetaxel has shown some activity in advanced gastric cancer. Recent phase I studies found low hematologic toxicity and a favourable toxicity…”
Get full text

A systematic review of the role of pulmonary irradiation in the management of primary bone tumours by Whelan, J. S., Burcombe, R. J., Janinis, J., Baldelli, A. M., Cassoni, A. M.

“…Introduction Adjuvant therapy in osteosarcoma (OS) and Ewing’s sarcoma (ES) is primarily directed towards treatment of subclinical lung disease. Before the…”
Get full text

Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: Relationships with tumor recurrence and resistance to adjuvant chemotherapy by Cascinu, S., Graziano, F., Valentini, M., Catalano, V., Giordani, P., Staccioli, M. P., Rossi, C., Baldelli, A. M., Grianti, C., Muretto, P., Catalano, G.

“…Background: The behaviour of colorectal carcinomas may depend on molecular properties of tumors. In node-positive colon cancer, we assessed the S-phase…”
Get full text

Neuroprotective effect of glutathione (GSH) on oxaliplatin (L-OHP)-based chemotherapy in advanced colorectal cancer patients (pts): a randomized double-blind placebo-controlled trial by Catalano, V., Cascinu, S., Labianca, R., Giordani, P., Mosconi, S., Cordella, L., Ubiali, E., Baldelli, A.M., Pessi, M.A., Catalano, G.

Get full text

Immunohistochemical determination of p53 protein does not predict clinical response in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil—leucovorin combination by Cascinu, S., Catalano, V., Aschele, C., Barni, S., Debernardis, D., Gallo, L., Bandelloni, R., Staccioli, M. P., Baldelli, A. M., Brenna, A., Valenti, A., Muretto, P., Catalano, G.

“…Background We assessed the hypothesis that a compromised p53 function could account for the non response of colon cancer patients with low thymidylate synthase…”
Get full text

An evaluation of potential neuroprotective effect of reduced-glutathione (GSH) on oxaliplatin (OXA) based chemotherapy in advanced colorectal cancer patients by Catalano, V., Giordani, P., Baldelli, A.M., Cordella, L., Catalano, G., Cascinu, S.

Get full text

Thymidylate synthase (TS) protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil (5FU) by Cascinu, S., Aschele, C., Barni, S., Debernardis, D., Baldo, C., Tunesi, G., Catalano, V., Giordani, P., Baldelli, A.M., Catalano, G.

Get full text

Locoregional treatments of unresectable liver metastases from colorectal cancer by Cascinu, S., Catalano, V., Baldelli, A.M., Scartozzi, M., Battelli, N., Graziano, F., Cellerino, R.

Get full text

A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer by Cascinu, S., Silva, R. R., Labianca, R., Barni, S., Mattioli, R., Martignoni, G., Frontini, L., Gasparini, G., Catalano, V., Baldelli, A. M., Giuliodori, L., Agostinelli, R., Catalano, G.

“…Purpose: This multicenter phase II study was designed to assess the efficacy of the alternating schedule of tomudex with methotrexate (MTX)/5-fluorouracil…”
Get full text

Liver metastases from colorectal cancer by CASCINU, S, CATALANO, V, SCARTOZZI, M, BALDELLI, A. M, CELLERINO, R

Get full text